448 related articles for article (PubMed ID: 33074248)
1. Stathmin-2: adding another piece to the puzzle of TDP-43 proteinopathies and neurodegeneration.
Glass JD
J Clin Invest; 2020 Nov; 130(11):5677-5680. PubMed ID: 33074248
[TBL] [Abstract][Full Text] [Related]
2. Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies.
Young AL; Vogel JW; Robinson JL; McMillan CT; Ossenkoppele R; Wolk DA; Irwin DJ; Elman L; Grossman M; Lee VMY; Lee EB; Hansson O
Brain; 2023 Jul; 146(7):2975-2988. PubMed ID: 37150879
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of
Baughn MW; Melamed Z; López-Erauskin J; Beccari MS; Ling K; Zuberi A; Presa M; Gonzalo-Gil E; Maimon R; Vazquez-Sanchez S; Chaturvedi S; Bravo-Hernández M; Taupin V; Moore S; Artates JW; Acks E; Ndayambaje IS; Agra de Almeida Quadros AR; Jafar-Nejad P; Rigo F; Bennett CF; Lutz C; Lagier-Tourenne C; Cleveland DW
Science; 2023 Mar; 379(6637):1140-1149. PubMed ID: 36927019
[TBL] [Abstract][Full Text] [Related]
4. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia.
Prudencio M; Humphrey J; Pickles S; Brown AL; Hill SE; Kachergus JM; Shi J; Heckman MG; Spiegel MR; Cook C; Song Y; Yue M; Daughrity LM; Carlomagno Y; Jansen-West K; de Castro CF; DeTure M; Koga S; Wang YC; Sivakumar P; Bodo C; Candalija A; Talbot K; Selvaraj BT; Burr K; Chandran S; Newcombe J; Lashley T; Hubbard I; Catalano D; Kim D; Propp N; Fennessey S; ; Fagegaltier D; Phatnani H; Secrier M; Fisher EM; Oskarsson B; van Blitterswijk M; Rademakers R; Graff-Radford NR; Boeve BF; Knopman DS; Petersen RC; Josephs KA; Thompson EA; Raj T; Ward M; Dickson DW; Gendron TF; Fratta P; Petrucelli L
J Clin Invest; 2020 Nov; 130(11):6080-6092. PubMed ID: 32790644
[TBL] [Abstract][Full Text] [Related]
5. Physiological functions and pathobiology of TDP-43 and FUS/TLS proteins.
Ratti A; Buratti E
J Neurochem; 2016 Aug; 138 Suppl 1():95-111. PubMed ID: 27015757
[TBL] [Abstract][Full Text] [Related]
6. Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer's disease.
Agra Almeida Quadros AR; Li Z; Wang X; Ndayambaje IS; Aryal S; Ramesh N; Nolan M; Jayakumar R; Han Y; Stillman H; Aguilar C; Wheeler HJ; Connors T; Lopez-Erauskin J; Baughn MW; Melamed Z; Beccari MS; Olmedo Martínez L; Canori M; Lee CZ; Moran L; Draper I; Kopin AS; Oakley DH; Dickson DW; Cleveland DW; Hyman BT; Das S; Ertekin-Taner N; Lagier-Tourenne C
Acta Neuropathol; 2024 Jan; 147(1):9. PubMed ID: 38175301
[TBL] [Abstract][Full Text] [Related]
7. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia.
Jovičić A; Paul JW; Gitler AD
J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014
[TBL] [Abstract][Full Text] [Related]
8. [FTLD/ALS as TDP-43 proteinopathies].
Ishihara T; Ariizumi Y; Shiga A; Yokoseki A; Sato T; Toyoshima Y; Kakita A; Takahashi H; Nishizawa M; Onodera O
Rinsho Shinkeigaku; 2010 Nov; 50(11):1022-4. PubMed ID: 21921552
[TBL] [Abstract][Full Text] [Related]
9. [Clinical and pathological spectrum of TDP-43 associated ALS].
Onodera O; Yokoseki A; Tan CF; Ishihara T; Nishiira Y; Toyoshima Y; Kakita A; Nishizawa M; Takahashi H
Rinsho Shinkeigaku; 2010 Nov; 50(11):940-2. PubMed ID: 21921519
[TBL] [Abstract][Full Text] [Related]
10. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.
Cascella R; Capitini C; Fani G; Dobson CM; Cecchi C; Chiti F
J Biol Chem; 2016 Sep; 291(37):19437-48. PubMed ID: 27445339
[TBL] [Abstract][Full Text] [Related]
11. O-GlcNAcylation of TDP-43 suppresses proteinopathies and promotes TDP-43's mRNA splicing activity.
Zhao MJ; Yao X; Wei P; Zhao C; Cheng M; Zhang D; Xue W; He WT; Xue W; Zuo X; Jiang LL; Luo Z; Song J; Shu WJ; Yuan HY; Liang Y; Sun H; Zhou Y; Zhou Y; Zheng L; Hu HY; Wang J; Du HN
EMBO Rep; 2021 Jun; 22(6):e51649. PubMed ID: 33855783
[TBL] [Abstract][Full Text] [Related]
12. Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy.
Krus KL; Strickland A; Yamada Y; Devault L; Schmidt RE; Bloom AJ; Milbrandt J; DiAntonio A
Cell Rep; 2022 Jun; 39(13):111001. PubMed ID: 35767949
[TBL] [Abstract][Full Text] [Related]
13. Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
Riku Y; Watanabe H; Yoshida M; Tatsumi S; Mimuro M; Iwasaki Y; Katsuno M; Iguchi Y; Masuda M; Senda J; Ishigaki S; Udagawa T; Sobue G
JAMA Neurol; 2014 Feb; 71(2):172-9. PubMed ID: 24378564
[TBL] [Abstract][Full Text] [Related]
14. [TDP-43 proteinopathies: ALS and frontotemporal dementias].
Prudlo J
Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S25-7. PubMed ID: 19685386
[TBL] [Abstract][Full Text] [Related]
15. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype.
Mann DMA; Snowden JS
Brain Pathol; 2017 Nov; 27(6):723-736. PubMed ID: 28100023
[TBL] [Abstract][Full Text] [Related]
16. Molecular neuropathology of TDP-43 proteinopathies.
Neumann M
Int J Mol Sci; 2009 Jan; 10(1):232-246. PubMed ID: 19333444
[TBL] [Abstract][Full Text] [Related]
17. TDP-43-mediated neurodegeneration: towards a loss-of-function hypothesis?
Vanden Broeck L; Callaerts P; Dermaut B
Trends Mol Med; 2014 Feb; 20(2):66-71. PubMed ID: 24355761
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers for diseases with TDP-43 pathology.
Steinacker P; Barschke P; Otto M
Mol Cell Neurosci; 2019 Jun; 97():43-59. PubMed ID: 30399416
[TBL] [Abstract][Full Text] [Related]
19. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72.
Murray ME; DeJesus-Hernandez M; Rutherford NJ; Baker M; Duara R; Graff-Radford NR; Wszolek ZK; Ferman TJ; Josephs KA; Boylan KB; Rademakers R; Dickson DW
Acta Neuropathol; 2011 Dec; 122(6):673-90. PubMed ID: 22083254
[TBL] [Abstract][Full Text] [Related]
20. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
